Lymphoma

Expert oncologists offer considerations for the use of CAR-T therapy and bispecific antibodies in follicular lymphoma and discuss potential challenges that may limit the use of these agents in clinical practice.

An overview of the evolving role of CAR-T therapy in patients with relapsed or refractory follicular lymphoma.

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.

Panelists review the previously presented patient case and discuss alternative treatment strategies in early disease progression with expert insight on preferred treatment approaches for this setting.

Expert oncologists discuss best practices surrounding treatment follow-up and monitoring for patients with relapsed or refractory follicular lymphoma.

Data from the phase 3 ECHELON-1 trial support the European Commission’s approval of brentuximab vedotin plus chemotherapy as a treatment for those with CD30-positive stage III Hodgkin lymphoma.

Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

CAR-HEMATOTOX scores may enable risk stratification of patients with mantle cell lymphoma prior to treatment with brexucabtagene autoleucel.

Investigators anticipate sharing final data from the phase 2 TELLOMAK trial assessing lacutamab among patients with cutaneous T-cell lymphoma in the fourth quarter of 2023.

Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.

An overview of available treatment options for relapsed or refractory follicular lymphoma and with considerations for treatment selection and expert insight on preferred treatment approaches in the second-line setting.

Complete responses in patients with pretreated relapsed/refractory mantle cell lymphoma treated with glofitamab appear to be early and enduring.

The biologic license application for odronextamab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma is based on data from the phase 1 ELM- 1 and phase 2 ELM-2 studies.

A panel of experts present that case of a 65-year-old woman with follicular lymphoma and discuss potential approaches for treatment in the relapsed or refractory setting.

Expert oncologists discuss the evolving treatment landscape for follicular lymphoma and highlight key advances that have contributed to improved treatment options.

The conditional marketing approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma is based on data from the phase 1/2 EPCORE NHL-1 study.

Jennifer L. Garson, PA-C, gave an overview of follicular lymphoma and how she manages adverse effects in her institution.

Several discrepancies in care must be considered to properly address psychological needs in patients with lymphoma, including patient/doctor communication, information provision, and applying distress guidelines.

KT-333 is under investigation as a treatment for adult patients with relapsed/refractory lymphomas, leukemias, and solid tumors in a phase 1 clinical trial.

Objective response rate appears to be numerically higher for patients receiving zanubrutinib for relapsed/refractory mantle cell lymphoma in the second-line setting than in later lines of treatment.

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory large B-cell lymphoma who are ineligible to undergo a transplant.

Data from the phase 2 JACKPOT8 PARTB study support the new drug application for golidocitinib as a treatment for relapsed/refractory peripheral T-cell lymphoma in China.

Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.

Investigators will assess AFM13 in combination with AB-101 as a treatment for those with relapsed or refractory Hodgkin lymphoma in the phase 2 LuminICE-203 trial.

Treatment with loncastuximab tesirine-lpyl in the safety run-in portion of the LOTIS-5 study appears to be promising, according to Michal Kwiatek, MD, PhD

Data from previous studies demonstrate that pretreatment levels of circulating tumor DNA may be prognostic in diffuse large B-cell lymphoma, according to Mark J. Roschewski, MD.